# Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

> **NCT01061411** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Clear Cell Sarcoma of the Kidney
- Recurrent Renal Cell Carcinoma
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** Dalteparin
- **OTHER:** Pharmacological Study
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT01061411
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-06
- **Primary completion:** 2015-10-14
- **Final completion:** 2017-04-21
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061411, "Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01061411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*